While a melanoma-fighting drug from Roche and Berkeley’s Plexxikon Inc. seemed to steal the American Society of Clinical Oncology show this weekend, it was Exelixis Inc.’s prostate cancer treatment that made headlines Monday.
Not for all the right reasons, though.
No comments:
Post a Comment